definiens: means, on a country - by - country and Product - by - Pro duct basis, the unit volume of each component of a Biosimilar Produ ct(s ) sold in such country in the Licensed Territor y by one ( 1 ) or more Third Party(ies ) in a calendar quarter achieves a market share equal to or higher than [ * * * ] of the unit volume of each component of the relevant Produ ct sold in such country by SGI, its Affiliates and ( sub)licensees . By way of example, but not limitati on, for Generic Competition for a Product to satisf y the definition hereunder, ( i ) the applicable Biosimilar Product must meet the definition of Biosimilar Pro duct for each of component of the relevant Product ( i.e., th ere must be a Biosimilar Product for both ( A ) the a pplicable SGI Antibody that specifically targets a Collaborat ion Antigen in the relevant Product, and ( B ) the AC TR T - cells ), and ( ii ) the unit volume of each component of such Biosimilar Product sold in the country the Licensed Territory by one ( 1 ) or more Third Party(ies ) in a calendar quarter must achieve a market share equal to or higher than [ * * * ] of the unit volume of each component of the relevant Product sold in such country by SGI, i ts Affiliates and ( sub)licensees . Unless otherwise agr eed by the Parties, the unit volumes of each compon ent of each Biosimilar Product sold during a calendar quar ter will be as reported by IMS America Ltd. of Plym outh Meeting, Pennsylvania ( ) or any successor to IMS or any other independent sales auditing firm reasonably agreed upon by the Parties